Table 2.
Genotype frequencies of ANXA5 gene promoter haplotypes in German RPL patients with anti-trophoblast antibodies and two different control groups
| Genotype | RPL patients all | RPL patients subgroup 1a | RPL patients subgroup 2 | Muenster fertile controls | PopGen controls | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Observed | Expectedb | Observed | Expected | Observed | Expected | Observed | Expected | Observed | Expected | |
| N/N | 66 (66 %) | 66.3 | 28 (66.7 %) | 27.4 | 38 (65.6 %) | 38.8 | 356 (71.2 %) | 343.6 | 415 (77.9 %) | 413.3 |
| N/M1 | 13 (13 %) | 13.1 | 7 (16.7 %) | 6.6 | 6 (10.3 %) | 6.6 | 87 (17.4 %) | 99.5 | 35 (6.6 %) | 47.8 |
| M1/M1 | 1 (1 %) | 0.6 | 0 (0 %) | 0.3 | 1 (1.7 %) | 0.2 | 16 (3.2 %) | 7.2 | 1 (0.2 %) | 1.5 |
| N/M2, M1/M2c | 19 (19 %) | 18.9 | 6 (14.3 %) | 7.4 | 13 (22.4 %) | 11.6 | 31 (6.2 %) | 48.4 | 77 (14.4 %) | 69.0 |
| M2/M2 | 1 (1 %) | 1.1 | 1 (2.3 %) | 0.3 | 0 (0 %) | 0.8 | 10 (2 %) | 1.4 | 5 (0.9 %) | 1.4 |
| Total | 100 | 100 | 42 | 42 | 58 | 58 | 500 | 500 | 533 | 533 |
% percentage, RPL recurrent pregnancy loss)
aSubgroup 1, JEG-3+ patients; subgroup 2, JEG-3- patients; bExpected: genotype frequency expected at Hardy-Weinberg equilibrium, calculated with the Genepop package; c: genotype M1/M2 was only observed in one patient, one Muenster and five PopGen controls